Listen to this page using ReadSpeaker
Posts tagged ganglion cells

Optogenetic Therapy Takes First Step Forward in Clinical Trial

Retrosense logoRetroSense Therapeutics has reported that three participants have received injections of its potential optogenetic therapy, known as RST-01, in a Phase I/II clinical trial. The patients were given the lowest dose of RST-01, and no adverse ocular events were observed. Furthermore, the treatment showed some biological activity, though RetroSense did not provide details about what that activity was or what it meant.

More information on safety and efficacy will likely be reported about the RetroSense trial after more trial participants have been observed over a longer period of time, and after discussions with the U.S. Food and Drug Administration. Continue Reading…

Optogenetics Workshop Sheds Light on Opportunities for Restoring Vision

Dr. Richard Masland, Massachusetts Eye and Ear Infirmary

Dr. Richard Masland, Massachusetts Eye and Ear Infirmary

Last Friday, the Foundation hosted an outstanding science workshop in Boston on the development of optogenetic therapies for restoring vision in people with advanced retinal diseases. We convened an impressive cadre of the world’s top retinal scientists — including experts from Japan, France, Italy and the United States, as well as local researchers from Harvard and MIT — to discuss available optogenetic technologies and advancing them into and through clinical trials.

Continue Reading…